Sign in

    Noah Kava • Jefferies

    Noah Kava's questions to Quest Diagnostics Inc (DGX) leadership

    Noah Kava's questions to Quest Diagnostics Inc (DGX) leadership • Q2 2025

    Question

    Noah Kava, on behalf of Tycho Peterson at Jefferies, asked for a breakdown of the drivers behind the revenue guidance increase, seeking the specific contributions from new tests like Haystack and AD Detect, acquisitions, and other factors.

    Answer

    CFO Sam Samad explained the guidance raise was driven by both acquisitions and organic strength. He updated the full-year organic revenue growth forecast to 3.5%-4%. He attributed this strength to strong utilization from new health plan access, robust performance from advanced diagnostics like AD Detect, and a significant 3.3% increase in organic revenue per requisition, while noting that the pricing outlook remains flattish.

    Ask Fintool Equity Research AI

    Noah Kava's questions to Quest Diagnostics Inc (DGX) leadership • Q1 2025

    Question

    Noah Kava, on behalf of Tycho Peterson, asked about the Haystack MRD test, specifically regarding the progress on commercial orders, timelines for reimbursement submissions, and plans for generating more clinical evidence.

    Answer

    James Davis, Chairman, CEO and President, confirmed that Quest began receiving commercial orders for the Haystack assay during the quarter from many of the 75 customers in the early experience program. He stated that the process of submitting for reimbursement and working on coding and coverage policies has just begun. He also noted that publications from ongoing clinical trials will continue to generate more evidence.

    Ask Fintool Equity Research AI